ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.70
0.13%
Dow Jones
38,884.26
0.08%
US Dollar vs MXN
16.9079
0.13%
Brent Oil
82.865
-0.73%
Bitcoin
62,996.22
-0.27%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Opiant Pharmaceuticals Inc (OPNT)

  7. Opiant Pharmaceuticals Inc (OPNT) Noticias

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:OPNT
FechaHoraFuenteTítuloSímboloCompañía
13/03/202305:16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:OPNTOpiant Pharmaceuticals Inc
10/03/202305:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202313:02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202312:17Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202308:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
27/02/202315:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
16/02/202316:14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
07/02/202315:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
06/02/202307:00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
19/01/202315:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
04/01/202315:21Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
21/12/202215:56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
22/11/202215:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202205:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202215:25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202203:26TipRanksHow Will Indivior’s $145M Purchase of Opiant Boost the Stock?NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202201:13GlobeNewswire Inc.Opiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202201:12GlobeNewswire Inc.Indivior PLC to Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202201:10PR Newswire (US)Indivior To Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/10/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/10/202207:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderNASDAQ:OPNTOpiant Pharmaceuticals Inc
22/08/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeNASDAQ:OPNTOpiant Pharmaceuticals Inc
12/08/202206:30PR Newswire (Canada)MindMed Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
08/08/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
02/08/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
01/08/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
28/06/202215:05GlobeNewswire Inc.Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
17/06/202215:54Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
08/06/202215:05GlobeNewswire Inc.Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OPNT

Su Consulta Reciente

COIN
SOLUSD
Solana
NYSE
NKE
Nike
FX
USDMXN
US Dollar vs MXN
NYSE
BAC
Bank of America
NASDAQ
QQQ
Invesco QQQ Trust Series 1
PM
XAUUSD
Gold vs US Dollar
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
AMEX
XLV
Health Care Select Sector
CCOM
US30
US 30
SPI
SP500
S&P 500
FX
EURUSD
Euro vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
AXP
American Express
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados